Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
- Author
- SPENCER, A1 ; HORVATH, N2 ; LOWENTHAL, R11 ; DEVERIDGE, S12 ; TAYLOR, K13 ; GIBSON, J3 ; PRINCE, H. M4 ; HERRMANN, R5 ; BASHFORD, J6 ; JOSKE, D7 ; GRIGG, A8 ; MCKENDRICK, J9 ; PROSSER, I10
[1] Clinical Haematology & BMT, The Alfred Hospital, Melbourne, Australia
[2] Division of Haematology, Institute of Medical & Veterinary Science, Adelaide, Australia
[3] Haematology Department, Royal Prince Alfred Hospital, Camperdown, Australia
[4] Haematolog Service, Peter MacCallum Cancer Centre, Melbourne, Australia
[5] Deportment of Haematology, Royal Perth Hospital, Perth, Australia
[6] Wesley Medical Centre, Auchenflower, Australia
[7] Haematology Clinics, Sir Charles Gardiner Hospital, Nedlands, Australia
[8] BMT Service, Royal Melbourne Hospital, Parkville, Australia
[9] Department of Oncology, Box Hill Hospital, Box Hill, Australia
[10] Haematology Department, The Canberra Hospital, Woden, Australia
[11] Clinical Haematology & Medical Oncology Unit, Royal Hobart Hospital, Hobart, Australia
[12] Hunter Haematology Unit, Newcastle Mater Misericordiae Hospital, Newcastle, Australia
[13] Department of Haematology, Mater Hospital, Brisbane, Australia
Australasian Leukaemia and Lymphoma Group, Australia - Source
Bone marrow transplantation (Basingstoke). 2005, Vol 35, Num 10, pp 971-977, 7 p ; ref : 35 ref
- CODEN
- BMTRE9
- ISSN
- 0268-3369
- Scientific domain
- Medical oncology; Graft, transplantation; Hematology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- amifostine high-dose chemotherapy mucositis myeloma
- Keyword (fr)
- Amifostine Anticancéreux Autogreffe Cellule hématopoïétique Cellule souche Chimiothérapie Cytoprotecteur Dose forte Essai clinique Homme Hématologie Melphalan Muqueuse pathologie Myélome Traitement Mucite Agent alkylant Greffe Hémopathie maligne Immunoglobulinopathie Immunopathologie Lymphoprolifératif syndrome
- Keyword (en)
- Amifostine Antineoplastic agent Autograft Hematopoietic cell Stem cell Chemotherapy Cytoprotector High dose Clinical trial Human Hematology Melphalan Mucosa disease Myeloma Treatment Mucositis Alkylating agent Graft Malignant hemopathy Immunoglobulinopathy Immunopathology Lymphoproliferative syndrome
- Keyword (es)
- Amifostina Anticanceroso Autoinjerto Célula hematopoyética Célula primitiva Quimioterapia Citoprotector Dosis fuerte Ensayo clínico Hombre Hematología Melfalán Mucosa patología Mieloma Tratamiento Agente alquilante Injerto Hemopatía maligna Inmunoglobulinopatía Inmunopatología Linfoproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D02 Immunoglobulinopathies
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B27 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy / 002B27D Transfusions. Complications. Transfusion reactions. Cell and gene therapy / 002B27D02 Bone marrow, stem cells transplantation. Graft versus host reaction
- Discipline
- Anaesthesia. Reanimation. Transfusion. Cell therapy and gene therapy Immunopathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16756403
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bmt.1704946 
https://dx.doi.org/10.1038/sj.bmt.1704946
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Bone marrow transplantation (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:37:\"Bone marrow transplant. (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"35\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"971\";s:8:\"\u0000*\u0000epage\";s:3:\"977\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0268-3369\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SPENCER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:10:\"HORVATH, N\";i:1;s:12:\"LOWENTHAL, R\";i:2;s:12:\"DEVERIDGE, S\";i:3;s:9:\"TAYLOR, K\";i:4;s:9:\"GIBSON, J\";i:5;s:12:\"PRINCE, H. M\";i:6;s:11:\"HERRMANN, R\";i:7;s:11:\"BASHFORD, J\";i:8;s:8:\"JOSKE, D\";i:9;s:8:\"GRIGG, A\";i:10;s:13:\"MCKENDRICK, J\";i:11;s:10:\"PROSSER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BMTRE9\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Bone marrow transplantation (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:37:\"Bone marrow transplant. (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"35\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"971\";s:8:\"\u0000*\u0000epage\";s:3:\"977\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0268-3369\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SPENCER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:10:\"HORVATH, N\";i:1;s:12:\"LOWENTHAL, R\";i:2;s:12:\"DEVERIDGE, S\";i:3;s:9:\"TAYLOR, K\";i:4;s:9:\"GIBSON, J\";i:5;s:12:\"PRINCE, H. M\";i:6;s:11:\"HERRMANN, R\";i:7;s:11:\"BASHFORD, J\";i:8;s:8:\"JOSKE, D\";i:9;s:8:\"GRIGG, A\";i:10;s:13:\"MCKENDRICK, J\";i:11;s:10:\"PROSSER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BMTRE9\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Bone marrow transplantation (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:37:\"Bone marrow transplant. (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"35\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"971\";s:8:\"\u0000*\u0000epage\";s:3:\"977\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0268-3369\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SPENCER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:10:\"HORVATH, N\";i:1;s:12:\"LOWENTHAL, R\";i:2;s:12:\"DEVERIDGE, S\";i:3;s:9:\"TAYLOR, K\";i:4;s:9:\"GIBSON, J\";i:5;s:12:\"PRINCE, H. M\";i:6;s:11:\"HERRMANN, R\";i:7;s:11:\"BASHFORD, J\";i:8;s:8:\"JOSKE, D\";i:9;s:8:\"GRIGG, A\";i:10;s:13:\"MCKENDRICK, J\";i:11;s:10:\"PROSSER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BMTRE9\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Bone marrow transplantation (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:37:\"Bone marrow transplant. (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"35\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"971\";s:8:\"\u0000*\u0000epage\";s:3:\"977\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0268-3369\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SPENCER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:10:\"HORVATH, N\";i:1;s:12:\"LOWENTHAL, R\";i:2;s:12:\"DEVERIDGE, S\";i:3;s:9:\"TAYLOR, K\";i:4;s:9:\"GIBSON, J\";i:5;s:12:\"PRINCE, H. M\";i:6;s:11:\"HERRMANN, R\";i:7;s:11:\"BASHFORD, J\";i:8;s:8:\"JOSKE, D\";i:9;s:8:\"GRIGG, A\";i:10;s:13:\"MCKENDRICK, J\";i:11;s:10:\"PROSSER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BMTRE9\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bmt.1704946\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:9:\"\u0000*\u0000jtitle\";s:41:\"Bone marrow transplantation (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:37:\"Bone marrow transplant. (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"35\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"971\";s:8:\"\u0000*\u0000epage\";s:3:\"977\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0268-3369\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"SPENCER\";s:10:\"\u0000*\u0000aufirst\";s:1:\"A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:10:\"HORVATH, N\";i:1;s:12:\"LOWENTHAL, R\";i:2;s:12:\"DEVERIDGE, S\";i:3;s:9:\"TAYLOR, K\";i:4;s:9:\"GIBSON, J\";i:5;s:12:\"PRINCE, H. M\";i:6;s:11:\"HERRMANN, R\";i:7;s:11:\"BASHFORD, J\";i:8;s:8:\"JOSKE, D\";i:9;s:8:\"GRIGG, A\";i:10;s:13:\"MCKENDRICK, J\";i:11;s:10:\"PROSSER, I\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BMTRE9\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:157:\"Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
